PEPVAC -- a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands
What you can do:
Develop fully covering multi-epitope vaccines against pathogenic organisms based on genome wide predictions of promiscuous MHCI-restricted epitopes.
Highlights:
- This Web server, PEPVAC (Promiscuous EPitope-based VACcine), is optimized for the formulation of multi-epitope vaccines with broad population coverage.
- This optimization is accomplished through the prediction of peptides that bind to several HLA molecules with similar peptide-binding specificity (supertypes).
- Specifically, it offers the possibility of identifying promiscuous peptide binders to five distinct HLA class I supertypes (A2, A3, B7, A24 and B15). It is estimated the phenotypic population frequency of these supertypes to be 95%, regardless of ethnicity.
- Targeting these supertypes for promiscuous peptide-binding predictions results in a limited number of potential epitopes without compromising the population coverage required for practical vaccine design considerations.
- PEPVAC can also identify conserved MHC ligands, as well as those with a C-terminus resulting from proteasomal cleavage. The combination of these features with the prediction of promiscuous HLA class I ligands further limits the number of potential epitopes.
Keywords:
- major histocompatibility complex
- MHC
- T-cell epitopes
- multi-epitope vaccines
- multi-epitope vaccines design tool
- human leukocyte antigens
- HLAs
- HLA-A Antigens
- HLA-B Antigens
- Proteasome Endopeptidase Complex
- promiscuous HLA class I ligands prediction tool
- conserved MHC ligands identification tool
Literature & Tutorials:
This record last updated: 04-25-2006